Verrica Q2 2026 Earnings: YCANTH Growth Was Masked by a Milestone Comparison

Verrica Pharmaceuticals (Nasdaq: VRCA) reported Q2 2026 revenue of $5.9 million, down 53.9% from $12.7 million a year earlier, while diluted EPS swung to a loss of $0.62 from income of $0.02. YCANTH demand and product revenue increased, but the absence of a prior-year milestone, higher Phase 3 spending, sales-force investment, and a legal settlement pushed the company to a $13.2 million GAAP net loss. Quarter-end cash was $11.2 million, with a new conditional credit facility potentially extending the cash runway into 2028.

Core financial results

The revenue decline primarily reflected a difficult comparison in license and collaboration revenue rather than weaker YCANTH product sales. The prior-year quarter included an $8.0 million one-time milestone from Torii, while Q2 2026 collaboration revenue mainly consisted of commercial supply for YCANTH’s launch in Japan.

Expenses increased as Verrica expanded its sales force and advanced YCANTH’s common-warts Phase 3 program. A $1.7 million legal settlement expense also affected GAAP results.

Business and pipeline performance

YCANTH dispensed applicator units reached 19,626, rising 46.1% year over year and 28.3% from the previous quarter. U.S. net product revenue increased more slowly, by 12.3% year over year and 18.7% sequentially, with the company attributing the revenue increase primarily to higher deliveries to distribution partners.

The unit and revenue measures track different points in the commercial channel: dispensed units represent product demand, while recognized product revenue reflects deliveries to distributors. They therefore should not be expected to move at identical rates in every quarter.

Verrica also continued enrolling patients in COVE-2, the first pivotal study of YCANTH for common warts. The first U.S. and Japanese patients were dosed in COVE-3 during the quarter, and topline results from the global Phase 3 program are currently expected in mid-2027.

For VP-315, Verrica presented Phase 2 basal cell carcinoma data that management said showed potential effects in both treated and untreated lesions. The company is continuing Phase 3 readiness activities, but it did not provide a Phase 3 start date.

YCANTH growth was masked by the milestone comparison

License and collaboration revenue fell by approximately $7.4 million, exceeding the $6.84 million decline in total revenue because the increase in YCANTH product revenue provided a partial offset. This makes the reported revenue contraction a poor standalone measure of the underlying direction of the U.S. YCANTH business.

The earnings reversal was broader than the revenue comparison. R&D expense rose by approximately $4.2 million to $6.0 million, mainly because of the common-warts Phase 3 program, while SG&A increased by approximately $1.5 million to $10.3 million as Verrica expanded its sales force. The $1.7 million legal settlement expense added further pressure. Lower interest expense following the November 2025 termination of the OrbiMed facility provided only a partial offset.

Profitability, liquidity, and the balance sheet

Verrica said the common-warts Phase 3 expense did not affect its cash balance because Torii will make the first $40 million of payments for the program under the companies’ collaboration and license agreement. This funding distinction is important because the R&D expense reduced reported earnings even though the related program cost was not funded from Verrica’s cash during the quarter.

Cash declined to $11.2 million at June 30, 2026, from $30.1 million at December 31, 2025. Over the same period, accounts receivable increased to $11.1 million from $5.4 million, while total liabilities rose to $31.7 million from $22.4 million. The balance sheet also included a $4.0 million legal settlement liability and a $2.3 million insurance recovery asset.

On August 6, Verrica entered into a credit agreement for up to $27.5 million with an entity controlled by Chairman and largest shareholder Paul B. Manning. Management said full availability of this facility, together with its current operating plan, could extend the company’s cash runway into 2028. That runway depends on Verrica satisfying the facility’s applicable conditions and obtaining the full amount.

Outlook

Verrica did not provide conventional revenue or EPS guidance, but it disclosed two quantitative operating and liquidity milestones. Both remain conditional rather than guaranteed outcomes.

Recent insider transactions

The supplied insider data reported no open-market purchases or sales during the most recent six-month period. In the separate two-year transaction list, the latest disclosed transaction was a stock grant in December 2025; the table below presents the ten most recent entries provided without inferring insider sentiment.

Risks investors should monitor

• Revenue concentration and milestone volatility: Collaboration milestones can create large year-over-year swings that obscure changes in recurring product revenue.
• Continued operating losses: Higher commercial and clinical-development spending contributed to a $13.2 million quarterly net loss even as YCANTH product revenue increased.
• Conditional liquidity outlook: The projected runway into 2028 assumes full access to the new $27.5 million credit facility and execution of the current operating plan.
• Clinical execution: The common-warts opportunity depends on successful enrollment, timely mid-2027 data, and the results of COVE-2 and COVE-3. VP-315 remains in Phase 3 readiness work without a disclosed start date.
• Commercial conversion: Rising dispensed units have not translated into product revenue at the same rate, making distributor deliveries and revenue recognition important indicators alongside patient demand.

Summary

Verrica’s Q2 2026 results showed improving YCANTH demand and product revenue, but those gains were outweighed in the reported totals by the absence of a prior-year milestone and sharply higher development and commercial expenses. The next major operating checkpoints are sustained YCANTH revenue conversion, progress in the common-warts Phase 3 studies, and access to the credit facility needed to support the stated cash runway.